BIOMAT Database Logo BIOMAT Database Logo

Efficacy of clindamycin vaginal ovule (3-day treatment) vs. clindamycin vaginal cream (7-day treatment) in bacterial vaginosis. 2001

J Sobel, and J F Peipert, and J A McGregor, and C Livengood, and M Martin, and J Robbins, and C P Wajszczuk
Division of Infectious Diseases, Detroit Medical Center, Wayne State University School of Medicine, MI 48201, USA.

OBJECTIVE To compare the efficacy and safety of a 3-day regimen of clindamycin vaginal ovules with a 7-day regimen of clindamycin vaginal cream for the treatment of bacterial vaginosis (BV). METHODS Women with a clinical diagnosis of BV were treated with a 3-day course of clindamycin ovules or a 7-day course of clindamycin cream administered intravaginally. Three hundred and eighty-four patients received study drug and were included in the evaluable patient population (ovule group, n = 204; cream group, n = 180). Assessments included pelvic examination and diagnostic testing. Primary efficacy endpoints were a resolution of two of three diagnostic criteria at the first follow-up visit and three of three diagnostic criteria at the second. RESULTS Cure rates in the evaluable patient population were similar between treatment groups: 53.7% (109/204) for the ovule group and 47.8% (85/180) for the cream group (p = 0.2471, 95% CI -4.1-16.0%). The most commonly reported medical event, vulvovaginal pruritus, had similar incidence in both treatment groups. CONCLUSIONS A 3-day course of clindamycin vaginal ovules is as effective and well-tolerated as a 7-day course of clindamycin vaginal cream in the treatment of BV.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002981 Clindamycin An antibacterial agent that is a semisynthetic analog of LINCOMYCIN. 7-Chloro-7-deoxylincomycin,Chlolincocin,Chlorlincocin,Cleocin,Clindamycin Hydrochloride,Clindamycin Monohydrochloride,Clindamycin Monohydrochloride, Monohydrate,Dalacin C,7 Chloro 7 deoxylincomycin,Hydrochloride, Clindamycin,Monohydrate Clindamycin Monohydrochloride,Monohydrochloride, Clindamycin,Monohydrochloride, Monohydrate Clindamycin
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000282 Administration, Intravaginal The insertion of drugs into the vagina to treat local infections, neoplasms, or to induce labor. The dosage forms may include medicated pessaries, irrigation fluids, and suppositories. Administration, Vaginal,Drug Administration, Vaginal,Instillation, Vaginal,Intravaginal Administration,Vaginal Drug Administration,Vaginal Administration,Administration, Vaginal Drug,Administrations, Intravaginal,Administrations, Vaginal,Administrations, Vaginal Drug,Drug Administrations, Vaginal,Instillations, Vaginal,Intravaginal Administrations,Vaginal Administrations,Vaginal Drug Administrations,Vaginal Instillation,Vaginal Instillations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

J Sobel, and J F Peipert, and J A McGregor, and C Livengood, and M Martin, and J Robbins, and C P Wajszczuk
Clindamycin vaginal cream vs oral metronidazole in the treatment of bacterial vaginosis.
January 1992, Archives of AIDS research,
J Sobel, and J F Peipert, and J A McGregor, and C Livengood, and M Martin, and J Robbins, and C P Wajszczuk
Efficacy of clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis.
September 1993, Obstetrics and gynecology,
J Sobel, and J F Peipert, and J A McGregor, and C Livengood, and M Martin, and J Robbins, and C P Wajszczuk
Comparison of clindamycin phosphate vaginal cream with triple sulfonamide vaginal cream in the treatment of bacterial vaginosis.
October 2001, Sexually transmitted diseases,
J Sobel, and J F Peipert, and J A McGregor, and C Livengood, and M Martin, and J Robbins, and C P Wajszczuk
Treatment of bacterial vaginosis with a three day course of 2% clindamycin vaginal cream: a pilot study.
April 1994, Genitourinary medicine,
J Sobel, and J F Peipert, and J A McGregor, and C Livengood, and M Martin, and J Robbins, and C P Wajszczuk
Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis.
September 1990, Obstetrics and gynecology,
J Sobel, and J F Peipert, and J A McGregor, and C Livengood, and M Martin, and J Robbins, and C P Wajszczuk
Treatment of bacterial vaginosis: a comparison of oral metronidazole, metronidazole vaginal gel, and clindamycin vaginal cream.
November 1995, The Journal of family practice,
J Sobel, and J F Peipert, and J A McGregor, and C Livengood, and M Martin, and J Robbins, and C P Wajszczuk
Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole.
June 1992, Obstetrics and gynecology,
J Sobel, and J F Peipert, and J A McGregor, and C Livengood, and M Martin, and J Robbins, and C P Wajszczuk
Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.
November 1992, Southern medical journal,
J Sobel, and J F Peipert, and J A McGregor, and C Livengood, and M Martin, and J Robbins, and C P Wajszczuk
Continuous versus interrupted use of vaginal probiotics plus vaginal clindamycin cream for bacterial vaginosis: a randomized controlled study.
January 2021, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians,
J Sobel, and J F Peipert, and J A McGregor, and C Livengood, and M Martin, and J Robbins, and C P Wajszczuk
[Treatment of vaginal yeast infections. 2% Clotrimazole vaginal cream in 3-day therapy and 1% econazolenitrate vaginal cream in 7-day therapy; clinical comparison].
July 1981, Fortschritte der Medizin,
Copied contents to your clipboard!